Skip to main content

Table 3 Crude incidence proportions for FN (broad definition) in cycle 1, cycle 2, cycles 3+, last cycle, and all cycles, respectively, by receipt of pegfilgrastim prophylaxis*

From: Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

  Commercial Medicare
  FN in Cycle   FN in Cycle
No. (%) in Each Category No Yes Unadjusted OR (95% CI) No. (%) in Each Category No Yes Unadjusted OR (95% CI)
Cycle 1 50,778 48,157 (95%) 2621 (5%)   71,037 64,249 (90%) 6788 (10%)  
 Use of Pegfilgrastim Prophylaxis
  No 16,512 (33%) 15,234 (92%) 1278 (8%) 20,195 (28%) 17,901 (89%) 2294 (11%)
  Yes 34,266 (67%) 32,923 (96%) 1343 (4%) 2.1 (1.9–2.2) 50,842 (72%) 46,348 (91%) 4494 (9%) 1.3 (1.3–1.4)
Cycle 2 41,769 40,810 (98%) 959 (2%)   59,412 56,343 (95%) 3069 (5%)  
 Use of Pegfilgrastim Prophylaxis
  No 11,719 (28%) 11,353 (97%) 366 (3%) 15,193 (26%) 14,282 (94%) 911 (6%)
  Yes 30,050 (72%) 29,457 (98%) 593 (2%) 1.6 (1.4–1.8) 44,219 (74%) 42,061 (95%) 2158 (5%) 1.2 (1.1–1.3)
Cycles ≥3 98,075 96,006 (98%) 2069 (2%)   141,495 134,363 (95%) 7132 (5%)  
 Use of Pegfilgrastim Prophylaxis
  No 24,834 (25%) 24,229 (98%) 605 (2%) 43,012 (30%) 40,842 (95%) 2170 (5%)
  Yes 73,241 (75%) 71,777 (98%) 1464 (2%) 1.2 (1.1–1.3) 98,483 (70%) 93,521 (95%) 4962 (5%) 1.0 (1.0–1.1)
Last Cycle 34,860 33,426 (96%) 1434 (4%)   51,989 45,392 (87%) 6597 (13%)  
 Use of Pegfilgrastim Prophylaxis
  No 10,188 (29%) 9705 (95%) 483 (5%) 20,099 (39%) 17,851 (89%) 2248 (11%)
  Yes 24,672 (71%) 23,721 (96%) 951 (4%) 1.2 (1.1–1.4) 31,890 (61%) 27,541 (86%) 4349 (14%) 0.8 (0.8–0.8)
All Cycles 190,622 184,973 (97%) 5649 (3%)   271,944 254,955 (94%) 16,989 (6%)  
 Use of Pegfilgrastim Prophylaxis
  No 53,065 (28%) 50,816 (96%) 2249 (4%) 78,400 (29%) 73,025 (93%) 5375 (7%)
  Yes 137,557 (72%) 134,157 (98%) 3400 (2%) 1.7 (1.7–1.8) 193,544 (71%) 181,930 (94%) 11,614 (6%) 1.2 (1.1–1.2)
  1. FN febrile neutropenia
  2. *Only consecutive qualifying cycles, beginning with cycle 1, were considered in this analysis